Skip to content

Advertisement

Volume 3 Supplement 2

21st European Workshop for Rheumatology Research

  • Meeting abstract
  • Open Access

The integration of functional genomics, combinatorial chemistry and nanotechnology into a miniaturized drug discovery process

  • 1
Arthritis Research & Therapy20013 (Suppl 2) :L005

https://doi.org/10.1186/ar153

  • Received: 15 January 2001
  • Published:

Keywords

  • Correlation Time
  • Functional Genomic
  • Discovery Process
  • Fluorescence Anisotropy
  • Fluorescence Technique

Future concepts in miniaturized HTScreening technologies will concentrate on making optimal use of the two emerging technologies, combinatorial chemistry and functional genomics. To effectively exploit compounds from highly-parallel combinatorial synthesis and the high number of new target proteins from functional genomics, Novartis and Evotec BioSystems developed the CONA-BSP (confocal nanoscanning - bead scanning picking technology) as a novel high throughput - low hit-rate HTS process. In combination with the Novartis proprietary AIDA-Technology, quantitative on-bead confocal fluorescence screening can be combined with off-bead confirmation via a series of fluorescence techniques such as fluorescence anisotropy, or rotational correlation time applied to equilibrium binding studies.

Single molecule fluorescence spectroscopy and confocal nanoscanning/AIDA technology provide an optimal combination for a miniaturized automated uHTS process with high mechanistic resolution in functional and coupled assay systems.

Authors’ Affiliations

(1)
Novartis Forschungsinstitut GmbH, Dermatology, Fluorescence based HTS-Technology Program, Vienna, Austria

References

  1. Fluorescence correlation spectroscopy: Lead discovery by miniaturized HTS.Google Scholar
  2. Auer M, Moore Keith, Meyer-Almes F-J, Guenther R, Pope AJ, Stoeckli KA: Drug Discovery Today,. 1998, 3: 457-465. 10.1016/S1359-6446(98)01240-9.View ArticleGoogle Scholar
  3. Auer M, Gstach H: Fluorescent dyes (AIDA) for solid phase and solution phase screening. United States Patent, WO 00/37448.Google Scholar
  4. Meyer-Almes FJ, Auer M: Enzyme inhibition assays with fluorescence correlation spectroscopy: A new algorithm for the derivation of kcat/Km and Ki values at substrate concentrations lower than the Michaelis Menten constant. Biochemistry. 2000, 39(43): 13261-13268. 10.1021/bi000057y.View ArticleGoogle Scholar
  5. The integration of single molecule detection technologies into miniaturized drug screening: Current status and future perspectives.Google Scholar
  6. Bühler C, Stöckli K, Auer M: . Review in press: Fluorescence Spectroscopy: Valeur/Brochon, Trends in Fluorescence Spectroscopy (Springer Verlag, 2001).Google Scholar

Copyright

Advertisement